WO2010087032A1 - 口腔内フィルム状基剤及び製剤 - Google Patents
口腔内フィルム状基剤及び製剤 Download PDFInfo
- Publication number
- WO2010087032A1 WO2010087032A1 PCT/JP2009/054335 JP2009054335W WO2010087032A1 WO 2010087032 A1 WO2010087032 A1 WO 2010087032A1 JP 2009054335 W JP2009054335 W JP 2009054335W WO 2010087032 A1 WO2010087032 A1 WO 2010087032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- film
- organic solvent
- oral
- soluble
- sugar
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to an oral film-form base that dissolves rapidly in the oral cavity, and a preparation containing a drug in the base, and more specifically, fine particles of sugar and sugar alcohol are dispersed in the base.
- the present invention relates to an oral film-form base and a preparation in which a drug is well absorbed by a digestive organ or oral mucosa by being rapidly dissolved in the oral cavity.
- solid preparations such as naked tablets, coated tablets, capsules, powders, granules, liquid preparations such as liquid preparations and emulsions are on the market.
- liquid preparations such as liquid preparations and emulsions
- disintegrating tablets and fast-dissolving oral film-form preparations are already on the market.
- over 10 products of over-the-counter (OTC) have already been sold overseas as film, tape or sheet preparations that can be applied to the oral cavity and taken up by saliva without being chewed.
- OTC over-the-counter
- one product is sold as an ethical drug and is also sold as an over-the-counter drug.
- hydroxypropylcellulose or a mixture of hydroxypropylcellulose and polyvinylpyrrolidone, a preparation base obtained by dissolving a tannin substance in a solvent and then removing the solvent Patent Document 1
- water-soluble And a coating layer comprising a non-water-absorbing polysaccharide and a softening agent
- a drug layer comprising a drug and an edible water-soluble polymer
- a drug layer comprising a drug, an edible water-soluble polymer and a tannin substance ( a film-like troche obtained by laminating c) in the order of a, b, c, b and a
- Patent Document 2 a drug and an edible polymer substance
- the film has a breaking strength of 200 to 3000 g / ⁇ 7 mm
- the film has a tensile strength of 200 to 3000 g / 15 mm and dissolves in the oral cavity within 60 seconds (patented) 3), an
- Patent Document 3 In Patent Document 4
- sugars and sugar alcohols are used in a state where they are dissolved in a solvent or recrystallized. Therefore, conventional oral film-form bases or preparations have a sticky feeling caused by a water-soluble polymer when applied to the oral cavity, and stickiness is also a problem when touched by fingers. It was.
- Patent Document 7 relating to a rapid-dissolving preparation does not show a technique for dispersing saccharide fine particles, and does not show a film-form preparation.
- the present invention has a rapid dissolution profile in the oral cavity and sufficient film strength, and further, the feeling of stickiness due to the water-soluble polymer in the oral cavity is reduced, and the tactile sensation when taken on the fingers is also improved.
- the object was to obtain an intraoral film-like base and preparation.
- an edible polymer that is soluble in water and an organic solvent having a solubility parameter of 9.7 or more and a sugar and a sugar alcohol that are not soluble in the organic solvent.
- a film-form base in which one or more kinds of sugar and sugar alcohol are dispersed in the organic solvent as fine particles is obtained, and a preparation using the same has a rapid dissolution profile and sufficient in the oral cavity. It has been found that the film has a strength and the touch when applied to the oral cavity and the touch when taken on the fingers are improved, and the present invention has been completed.
- the present invention relates to the following [1] to [11].
- [1] One or more edible polymers that are soluble in water and an organic solvent having a solubility parameter of 9.7 or more, and monosaccharide to hexasaccharide sugars having an average particle size of 0.1 ⁇ m to 60 ⁇ m
- an oral film-form base containing one or more particles selected from the group consisting of these sugar alcohols.
- a method for producing an intraoral film base [9] In an organic solvent having a solubility parameter of 9.7 or more, one or more drugs, water, and an edible polymer soluble in the organic solvent, and an average particle size of 0.1 ⁇ m to 60 ⁇ m One or more kinds of particles selected from the group consisting of monosaccharide to hexasaccharide sugars and these sugar alcohols are dissolved or dispersed, and a thin layer of the resulting dispersion is formed and dried.
- a method for producing an oral film-form preparation In an organic solvent having a solubility parameter of 9.7 or more, one or more drugs, water, and an edible polymer soluble in the organic solvent, and an average particle size of 0.1 ⁇ m to 60 ⁇ m One or more kinds of particles selected from the group consisting of monosaccharide to hexasaccharide sugars and these sugar alcohols are dissolved or dispersed, and a thin layer of the resulting dispersion is formed and dried.
- an organic solvent having a solubility parameter of 9.7 or more water or one or more edible polymers that are soluble in the organic solvent are dissolved, and the solution has an average particle size of One or more particles selected from the group consisting of monosaccharide to hexasaccharide sugars of 0.1 ⁇ m to 60 ⁇ m and these sugar alcohols were dispersed in the remainder of the organic solvent having a solubility parameter of 9.7 or more.
- a method for producing an oral film-form base comprising mixing in addition to the product, forming a thin layer of the resulting dispersion and drying.
- an organic solvent having a solubility parameter of 9.7 or more water and one or more edible polymers that are soluble in the organic solvent are dissolved, and the solution is averaged with a drug.
- One or more kinds of particles selected from the group consisting of monosaccharide to hexasaccharide sugars having a particle size of 0.1 ⁇ m to 60 ⁇ m and these sugar alcohols are used as the remainder of the organic solvent having a solubility parameter of 9.7 or more.
- a method for producing an oral film-form preparation comprising mixing in addition to a dissolved or dispersed mixture, forming a thin layer of the resulting dispersion and drying.
- one or more selected from sugar and sugar alcohol are dispersed in the form of particles, and a rapid dissolution profile in the oral cavity and sufficient film strength
- the sticky feeling caused by the water-soluble polymer when applied to the oral cavity is reduced, and the characteristics such as touch feeling when picked up by a finger are clearly improved as compared with conventional products. That is, by dispersing one or more selected from sugar and sugar alcohol uniformly in the film in the form of particles, film properties such as tensile strength and bending resistance required as a base and preparation can be obtained. Without loss, it is possible to clearly improve only the properties necessary for improving the dosage of the preparation, such as disintegration in the oral cavity, feel when applied to the oral cavity, and feel of the film.
- FIG. 1 is a schematic view showing an embodiment of an intraoral film base and a preparation according to the present invention.
- FIG. 2 is a schematic diagram showing how the tack duration time is measured.
- FIG. 3 is a diagram (magnification: 1000 times) showing the surface of the intraoral film-form base of Example 21 of the present invention.
- FIG. 4 is a diagram (magnification: 1000 times) showing the surface of the oral film-form base of Example 22 of the present invention.
- FIG. 5 is a diagram (magnification: 500 times) showing the surface of the oral film-form base of Example 23 of the present invention.
- the oral film-form base according to the present invention has one or more edible polymers that are soluble in water and an organic solvent having a solubility parameter of 9.7 or more, and an average particle size of 0.1 ⁇ m to 60 ⁇ m. 1 type or 2 or more types of particle
- FIG. 1 schematically shows an embodiment of the base, in which one or more particles (1a) of the sugar and sugar alcohol are contained in the film (1b) containing the edible polymer. It is thought that it is in a state of being uniformly dispersed.
- one or more particles (1a) of sugar and sugar alcohol are uniformly dispersed in a film (1b) containing an edible polymer and a drug. It is thought that.
- an edible polymer that is soluble in both water and an organic solvent having a solubility parameter of 9.7 or more, the organic compound having film-forming ability and edible, and in which sugar and sugar alcohol do not dissolve.
- Any solvent that can be dissolved in a solvent can be used without particular limitation.
- “edible” means that it can be administered orally and is pharmaceutically acceptable.
- polyvinylpyrrolidone is sufficiently soluble in water and an organic solvent having a solubility parameter of 9.7 or more, can be rapidly dissolved in the oral cavity, and can be used in production.
- PVP polyvinylpyrrolidone
- HPC hydroxypropylcellulose
- the PVP used as the edible polymer preferably has a weight average molecular weight of 2,500 to 3,000,000, more preferably 2,500 to 1,200,000. If the weight average molecular weight is less than 2,500, the stability and hygroscopicity of the resulting base and the preparation may be reduced. Conversely, if it exceeds 3,000,000, the solubility parameter is 9.7 or more. There is a possibility that the solubility in an organic solvent may decrease.
- the HPC used as the edible polymer preferably has a weight average molecular weight of 10,000 to 1,200,000, more preferably 10,000 to 370,000. If the weight average molecular weight is less than 10,000, the stability and hygroscopicity of the resulting base and the preparation may be reduced. Conversely, if it exceeds 1,200,000, the solubility parameter is 9.7 or more. There is a possibility that the solubility in an organic solvent may decrease.
- the weight average molecular weight of the PVP and HPC can be obtained by gel permeation chromatography analysis.
- the HPC used as the edible polymer in the present invention preferably has a hydroxypropoxy group substitution degree of 50% to 100%.
- the degree of substitution of the hydroxypropoxy group is a value quantified by the quantification method described in the “Hydroxypropylcellulose” section of the 15th revision Japanese Pharmacopoeia / Pharmaceutical Articles.
- the thing whose substitution degree of the said hydroxypropoxy group is 53.4% or more is preferable. This is because when the degree of substitution of the hydroxypropoxy group is less than 53.4%, the solubility in water and an organic solvent having a solubility parameter of 9.7 or more may be deteriorated.
- the upper limit of the hydroxypropoxy substitution degree of HPC used in the present invention is more preferably about 77.5% as defined in the 15th revised Japanese Pharmacopoeia / Pharmaceutical Articles.
- These edible polymers may be used alone or in combination of two or more.
- As the edible polymer it is convenient to use a commercially available product provided for pharmaceutical use.
- the blending amount of one or more of these edible polymers is suitably 10 to 80% by weight with respect to the total weight of the oral film-like base or preparation according to the present invention. More preferably, it is set to ⁇ 70% by weight. If the blending amount of the edible polymer is less than 10% by weight, the film becomes brittle and does not exhibit sufficient strength, and if it exceeds 80% by weight, a sticky feeling derived from the polymer in the oral cavity tends to occur. Because.
- edible polymers that are soluble in both water and organic solvents having a solubility parameter of 9.7 or more edible polymers that are soluble only in water, water and organic solvents.
- An appropriate amount of edible polymers that do not dissolve can also be used in combination.
- Examples of such edible polymers include acacia gum, gum arabic, sodium alginate, casein, xanthan gum, guar gum, dextran, tragacanth gum, starch, pullulan, pectin, and other natural compounds, crystalline cellulose, methylcellulose, ethylcellulose, Semi-synthetic polymer compounds such as carboxymethyl cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, carboxymethyl starch sodium, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, low-substituted hydroxypropyl cellulose, and synthetic polymer compounds such as polyvinyl alcohol and carboxyvinyl polymer A commercially available product that is provided for pharmaceuticals can be used.
- edible polymers that are soluble in both the above water and an organic solvent having a solubility parameter of 9.7 or more, monosaccharide to hexasaccharide sugars and particles of these sugar alcohols as shown below Is used.
- monosaccharides include aldoterose such as erythrose and throse, ribose, lyxose, aldopentose such as xylose and arabinose, allose, talose, gulose, glucose, altrose, mannose, galactose, idose and other aldhexoses, erythrulose Keto pentose such as ketotetrose, xylulose and ribulose, ketohexose such as psicose, fructose, sorbose and tagatose.
- aldoterose such as erythrose and throse
- ribose ribose
- lyxose aldopentose
- aldopentose such as xylose and arabinose
- allose talose
- gulose glucose
- altrose mannose
- galactose galactose
- disaccharides examples include ⁇ -diglucosides such as trehalose, cordobiose, nigerose, maltose and isomaltose, ⁇ -diglucosides such as isotrehalose, sophorose, laminaribiose, cellobiose and gentiobiose, and ⁇ , ⁇ -diglucosides such as neotrehalose. , Lactose, sucrose, isomaltulose (palatinose) and the like. Examples of the trisaccharide include raffinose.
- trisaccharide to hexasaccharide oligosaccharide examples include fructooligosaccharide, galactooligosaccharide, xylo-oligosaccharide, isomaltoligosaccharide, chitin oligosaccharide, chitosan oligosaccharide, oligoglucosamine, and cyclodextrin. And cyclic oligosaccharides.
- Monosaccharide sugar alcohols include erythritol, D-threitol, L-threitol and other tetritols, D-arabinitol, xylitol and other pentitols, D-idinol, galactitol (dulcitol), D-glucitol (sorbitol), mannitol, etc. And cyclitols such as hexitol and inositol.
- disaccharide sugar alcohols include maltitol, lactitol, and reduced palatinose (isomalt)
- examples of oligosaccharides include pentaerythritol and reduced maltose starch syrup.
- monosaccharides to trisaccharides and sugar alcohols thereof are preferably used. Furthermore, lactose, erythritol, xylitol, mannitol, and reduced palatinose (isomalt) having low hygroscopicity are more preferable.
- lactose, erythritol, xylitol, mannitol, and reduced palatinose (isomalt) having low hygroscopicity are more preferable.
- one or more of the above-mentioned monosaccharide to hexasaccharide sugars and these sugar alcohols are selected and used.
- those containing particles having an average particle size of 0.1 ⁇ m to 60 ⁇ m are used as one or more selected from the above-mentioned monosaccharide to hexasaccharide sugars and sugar alcohols thereof.
- the sugar and sugar alcohol those containing 30 to 80% by weight of particles having the above average particle diameter with respect to the total content of sugar and sugar alcohol in the base or the preparation are preferable. If the average particle size of one or more selected from sugar and sugar alcohol is less than 0.1 ⁇ m, each particle may be aggregated, and the flexibility of the film base or formulation is uneven depending on the site There is a possibility.
- the flexibility of the preparation may also be uneven depending on the site when it is contained in a film-like base or preparation having a practical thickness.
- one or more selected from sugar and sugar alcohol are more preferably those containing particles having an average particle diameter of 0.1 to 30 ⁇ m.
- the average particle diameter of one type or two or more types of particles selected from sugar and sugar alcohol refers to a 50% by volume average particle size measured by a laser scattering particle size distribution analyzer as follows. That is, 10 mg of sugar or sugar alcohol particles were added to 3 mL of a chloroform solution of 0.2% by weight of polyoxyethylene monolaurate and sufficiently dispersed by ultrasonic waves. This dispersion is added to chloroform so that the transmittance in a laser scattering type particle size distribution measuring apparatus (LA-950, manufactured by Horiba, Ltd.) is 75% to 85%, and 50 volume% average particle diameter is measured by a wet method. did.
- LA-950 laser scattering type particle size distribution measuring apparatus
- the sugar and sugar alcohol it is convenient to use commercially available products provided for pharmaceuticals, and those having an average particle size in the above range are sized. It can also be used, and a commercially available product can be used after being sized so that the average particle diameter is in the above range.
- the average particle diameter can be adjusted by pulverization, granulation by a dry granulation method, wet granulation method, etc., classification using a sieve or a classifier.
- solubility of edible polymers and sugars and sugar alcohols used in the present invention in water or organic solvents having a solubility parameter of 9.7 or higher it is necessary to dissolve 1 g of solute at 20 ° C.
- water or the organic solvent is 100 mL or more
- the expression “does not dissolve” is used, and when water or the organic solvent necessary to dissolve 1 g of solute is less than 5 mL, it is “soluble”. Expression is used.
- the expression “easily soluble” is used when the water or the organic solvent necessary for dissolving 1 g of solute is less than 3 mL.
- the sugar and sugar alcohol used in the present invention have low solubility in the organic solvent, but it is known that the solubility decreases as the temperature of the organic solvent increases. And can stabilize the particle state of sugar and sugar alcohol.
- the oral film-form base and preparation according to the present invention may optionally include a plasticizer such as polyethylene glycol, Surfactants, stabilizers, preservatives, antioxidants, fragrances, flavoring agents, sweetening agents, coloring agents, and the like can be appropriately blended.
- a plasticizer such as polyethylene glycol, Surfactants, stabilizers, preservatives, antioxidants, fragrances, flavoring agents, sweetening agents, coloring agents, and the like can be appropriately blended.
- the drug that can be blended in the oral film-form preparation according to the present invention is not particularly limited as long as it can be administered orally, and includes, for example, antineoplastic, anti-inflammatory, antiallergic, antidiabetic, Lipidemia treatment, bone / calcium metabolism, antihypertensive, angina treatment, antiarrhythmic, vasodilator, diuretic, bronchodilator, bronchial asthma, antitussive, expectorant, digestive stomach Drugs, gastrointestinal function regulators, peptic ulcer drugs, bowel disease drugs, laxatives, antipsychotics, antidepressants, mood stabilizers, psychostimulants, sleeping pills, anti-anxiety drugs, antiepileptic drugs, migraine treatment Drugs, antiemetics, antipruritics, Parkinson's disease drugs, cerebral circulation / metabolism improving drugs, anti-dementia drugs, antibacterial drugs, antiviral drugs, antifungal drugs, frequent urination / urination disorder drugs, urinary incontinence drugs
- the amount of these drugs varies depending on the type and titer of the drug, the symptoms of the patient to be applied, etc., but considering the required dose, etc., it is usually 0.1 to 60% by weight with respect to the total weight of the preparation. It is.
- drugs include zolmitriptan, diphenhydramine, tamsulosin, granisetron, tolterodine, scopolamine, famotidine, candesartan cilexetil, pioglitazone, amlodipine, donepezil, and salts thereof.
- a drug without bitterness is suitable as the drug used in the present invention. It can be used by adding bitterness masking techniques, bitterness masking agents, sweeteners, flavoring agents, and fragrances. Moreover, since many sugars and sugar alcohols used in the present invention exhibit sweetness, a masking effect on the bitterness of the drug can be expected.
- the thickness of the film base and the preparation according to the present invention is not particularly limited, but is preferably 30 to 300 ⁇ m. If the thickness is less than 30 ⁇ m, the film strength may be reduced, and the handling of the preparation may be deteriorated. If the thickness exceeds 300 ⁇ m, it takes time to dissolve in the oral cavity and may not be easily dissolved.
- a normal form can be adopted, and examples thereof include a rectangle, a square, a circle, and an ellipse.
- the intraoral film-form base according to the present invention has one or more edible polymers that are soluble in an organic solvent having a solubility parameter of 9.7 or more, water, and an average particle size.
- One or two or more kinds of particles selected from the group consisting of monosaccharide to hexasaccharide of 0.1 ⁇ m to 60 ⁇ m and these sugar alcohols are dissolved or dispersed to form a thin layer of the resulting dispersion. And dried.
- an organic solvent having a solubility parameter of 9.7 or more, one or more drugs, water, and one or more edible polymers that are soluble in the organic solvent, and an average particle size is One or two or more kinds of particles selected from the group consisting of monosaccharide to hexasaccharide sugars of 0.1 ⁇ m to 60 ⁇ m and these sugar alcohols can be dissolved or dispersed and produced in the same manner as described above.
- a predetermined amount of edible polymer is dissolved in a part of an organic solvent having a solubility parameter of 9.7 or more in which the polymer is soluble.
- one or two or more kinds of particles selected from the group consisting of sugar and sugar alcohol are adjusted in advance by a process such as pulverization, granulation, classification, etc. Disperse.
- the organic solvent solution of the edible polymer is added and mixed with other additive components such as a plasticizer if necessary, and an appropriate amount is spread on a release film made of polystyrene or polyethylene terephthalate. Dry to obtain a film base.
- the organic solvent in which the edible polymer is dissolved is preferably 1 to 2 times the amount of the edible polymer.
- the drug is dissolved or dispersed in the remainder of the organic solvent having a solubility parameter of 9.7 or more, and one or more kinds of particles selected from sugar and sugar alcohol are further dispersed. Thereafter, a solution in which an edible polymer is dissolved in a part of the organic solvent is added to this together with other additive components such as a plasticizer, if necessary. An appropriate amount of this liquid is spread and dried on the release film in the same manner as described above, cut into a desired shape and size, and hermetically sealed as necessary to obtain an oral film-form preparation.
- organic solvent having the solubility parameter of 9.7 or more used for the production of the oral film-form preparation according to the present invention sugar or sugar alcohol is not dissolved, but edible polymer may be dissolved, for example, Examples include methanol, ethanol, isopropanol, propylene glycol, methylene chloride, and acetone. One selected from these may be used alone, or two or more may be used in combination. Furthermore, lower alcohols such as methanol, ethanol and isopropanol, methylene chloride and acetone are preferably used, and purified water can be added if the amount is small. Further, when bubbles are generated in the solution at the time of preparation, the solution is left to stand overnight or defoamed by vacuum degassing.
- the “solubility parameter” refers to the square root (SP value) of heat of vaporization (cal / cm 3 ) necessary for evaporating a 1 mol volume of liquid.
- SP value square root
- the solubility parameter values of the organic solvent and water that can be used in the present invention are shown in Table 1.
- the solubility parameter of the organic solvent used in the present invention is preferably from 9.7 to 20 and more preferably from 9.7 to 15. If the solubility parameter exceeds 20, sugar or sugar alcohol may be dissolved, which is not preferable for the purpose of the present invention.
- the particles were sieved through a 32 ⁇ m, 50 ⁇ m or 90 ⁇ m sieve, and the 50% by volume average particle size was measured with a laser scattering particle size distribution measuring device. Used as an index of the particle size of the fine particles. Table 2 shows the 50 vol% average particle diameter of the sugar and sugar alcohol particles used.
- the oral film-form preparations of Examples 1 and 2 were prepared as follows.
- zolmitriptan was added and dissolved by stirring, and 40.0 parts by weight of D-mannitol fine particles obtained by passing a 32 ⁇ m sieve in advance were added and stirred ultrasonically.
- the oral film-form preparations of Comparative Examples 1 and 2 were prepared as follows.
- Table 3 9.0 parts by weight of zolmitriptan was added to 33.3 parts by weight of ethanol and dissolved by heating.
- purified water 47.0 parts by weight of pullulan or hydroxypropylmethylcellulose, 4.0 parts by weight of polyethylene glycol, and 40.0 parts by weight of D-mannitol fine particles obtained by previously sieving a 32 ⁇ m sieve were added and dissolved by stirring.
- the prepared ethanol solution of zolmitriptan was added and dissolved by stirring while heating at 45 ° C.
- Table 4 shows the compositions of Examples 3 to 10 for the oral film-form preparation of the present invention.
- these were prepared by dissolving zolmitriptan in ethanol, and then adding and dispersing fine particles of sugar or sugar alcohol that had previously been sieved through a 32 ⁇ m sieve.
- a solution prepared by adding HPC to 70.5 parts by weight, and polyethylene glycol were added and mixed by stirring. After sufficient defoaming, this was stretched and dried on a release film made of polyethylene terephthalate to give a film having a thickness of about 100 ⁇ m. And the obtained film was cut into a 3 cm 2 rectangle and prepared.
- Examples 11 to 20 The compositions of Examples 11 to 20 for the oral film-form preparation according to the present invention are shown in Table 6.
- Table 7 shows the compositions of Examples 21 to 26 for the oral film-form base according to the present invention.
- the solution was stirred and dissolved in 1 weight-fold ethanol to prepare an ethanol solution of HPC.
- the ethanol solution of HPC and polyethylene glycol were added and stirred and mixed, and this was stretched and dried on a polyethylene terephthalate release film, A film having a thickness of about 100 ⁇ m was produced, and the obtained film was cut into a 3 cm 2 rectangle to obtain a film-like base.
- the peel strength test and the softness test were conducted with respect to film strength, stickiness in the mouth, dissolution profile in the mouth, and feel when taken on the fingers, respectively. Measurement and evaluation were performed by performing a degree test, a tensile strength test, a tack duration test, an oral disintegration test, and a sensory evaluation (tactile sensation). Further, the average particle diameter of the sugar and sugar alcohol fine particles dispersed in the film base was measured using a microscope. Each test method is shown below.
- the bending resistance is indicated by the length (mm) when the test piece is moved, measured by reversing the front and back and front and back of each of the five test pieces, and calculating the average value of each to obtain the bending resistance. It was.
- the evaluation criteria were set as follows, considering the bending resistance (about 60 mm) of the film-form preparation (Comparative Example 3) when no sugar was added. In addition, the thing which was not able to peel from a peeling film on the physical property of the prepared sample and was unable to obtain a film-form preparation was set to 0 point.
- Tack duration test This test was performed using a rheometer (SUN SCIENTIFIC, CR-2000) by cutting each film-form preparation or base into a circle having a diameter of 12 mm to obtain a test piece.
- tac refers to a force that adheres to an adherend when it is brought into contact with the adherend in a short time with a light force.
- the appearance of the test is shown in FIG. That is, the test piece 2c is stuck on the probe 2a having a diameter of 12 mm with a double-sided tape 2b. Separately, a rubber 2e is placed on the test table 2f, and a collagen film 2d soaked in water is placed thereon.
- the probe 2a to which the test piece 2c is attached is lowered and brought into contact with the collagen film 2d, and then raised.
- the tack duration after the initial tack obtained when the probe 2a was separated from the collagen film 2d was measured from the recording paper using calipers.
- the measurement results were scored according to the following evaluation criteria. In addition, due to the physical properties of the prepared sample, those that could not be peeled off from the release film and could not obtain a film-form preparation were cut together with the release film, and the release film side was affixed to the double-sided tape of the probe. The measurement was performed in the same manner.
- Oral disintegration test 900 mL of a phosphate buffer solution of pH 6.8 is put into a 1000 mL glass petri dish, and a stainless steel sieve ( ⁇ 4 mm) is turned upside down and stirred in a stirrer (300 rpm). The temperature of this solution is controlled at 37 ⁇ 2 ° C. using a constant temperature water circulator, and a test piece (3 cm 2 ) is submerged therein, and at the same time, a 3 cm ⁇ 3 cm stainless steel wire mesh (mesh size 5 mm) is placed as a weight. It was. The appearance of the test piece was observed visually, and the time from when the test piece was submerged until the test piece completely collapsed was measured with a stopwatch.
- the oral disintegration time was scored according to the following evaluation criteria. In addition, the thing which was not able to peel from a peeling film on the physical property of the prepared sample and was unable to obtain a film-form preparation was set to 0 point.
- Table 8 shows the results of the evaluations and tests of (1) to (6) above for the oral film-form preparations of Examples 1 to 10.
- Table 9 shows the results of the evaluations and tests of (1) to (6) above for the oral film-form preparations of Comparative Examples 1 to 13.
- the oral film-form preparation of Comparative Example 1 prepared by dissolving pullulan, which is an edible polymer that is water-soluble but hardly soluble in ethanol, in purified water has good evaluation in all items. It was not obtained.
- the oral film-form preparation of Comparative Example 2 using hydroxypropylmethylcellulose, which is an edible polymer that is water-soluble but hardly soluble in ethanol has low strength against bending deformation and has a sticky feeling. It was.
- the oral film-form preparation of Comparative Example 3 in which no sugar or sugar alcohol fine particles were blended the disintegration property in the oral cavity was poor and the gooey feeling was remarkable.
- Table 10 shows the results of the evaluations and tests of (1) to (6) above for the oral film-form preparations of Examples 11 to 20.
- Table 11 shows the results of the evaluations and tests of (1) to (6) above for the oral film-form bases of Examples 21 to 26.
- Table 12 shows the average particle diameter measurement results for the oral film-form bases of Examples 21 to 23. Moreover, photographs under the microscope are shown in FIGS.
- the 50% by volume average particle diameter of the D-mannitol fine particles was also compared with that in the film-form base before addition. It was shown that D-mannitol was dispersed in the form of fine particles without dissolving in the base. As shown in FIGS. 3 to 5, good dispersion of D-mannitol fine particles could be confirmed by observation of the oral film-form bases of Examples 21 to 23 with a microscope.
- an intraoral film-form base having sufficient film strength, showing a rapid dissolution profile in the oral cavity, reduced stickiness in the oral cavity, and improved tactile sensation when taken on the fingers And formulations can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
[1]水及び溶解パラメーターが9.7以上の有機溶媒に可溶性である可食性高分子の1種又は2種以上と、平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を含有する、口腔内フィルム状基剤。
[2]糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子の平均粒子径が、0.1μm~30μmである、上記[1]に記載の口腔内フィルム状基剤。
[3]水及び溶解パラメーターが9.7以上の有機溶媒に可溶性である可食性高分子が、ポリビニルピロリドン及びヒドロキシプロピルセルロースからなる群より選ばれる1種又は2種以上である、上記[1]又は[2]に記載の口腔内フィルム状基剤。
[4]ポリビニルピロリドンの重量平均分子量が、2,500~3,000,000である、上記[3]に記載の口腔内フィルム状基剤。
[5]ヒドロキシプロピルセルロースの重量平均分子量が、10,000~1,200,000である、上記[3]に記載の口腔内フィルム状基剤。
[6]ヒドロキシプロピルセルロースのヒドロキシプロポキシ基置換度が、50%~100%である、上記[3]又は[5]に記載の口腔内フィルム状基剤。
[7]上記[1]~[6]のいずれか1項に記載したフィルム状基剤に、薬物を含有させてなる、口腔内フィルム状製剤。
[8]溶解パラメーターが9.7以上の有機溶媒に、水及び該有機溶媒に可溶性である可食性高分子の1種又は2種以上、及び平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を溶解又は分散させ、得られた分散液の薄層を形成させて乾燥することを特徴とする、口腔内フィルム状基剤の製造方法。
[9]溶解パラメーターが9.7以上の有機溶媒に、薬物、水及び該有機溶媒に可溶性である可食性高分子の1種又は2種以上、及び平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を溶解又は分散させ、得られた分散液の薄層を形成させて乾燥することを特徴とする、口腔内フィルム状製剤の製造方法。
[10]溶解パラメーターが9.7以上の有機溶媒の一部に、水及び該有機溶媒に可溶性である可食性高分子の1種又は2種以上を溶解させ、該溶液を、平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を溶解パラメーターが9.7以上の有機溶媒の残部に分散させたものに加えて混合し、得られた分散液の薄層を形成させて乾燥することを特徴とする、口腔内フィルム状基剤の製造方法。
[11]溶解パラメーターが9.7以上の有機溶媒の一部に、水及び該有機溶媒に可溶性である可食性高分子の1種又は2種以上を溶解させ、該溶液を、薬物と、平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を溶解パラメーターが9.7以上の有機溶媒の残部に溶解又は分散させたものに加えて混合し、得られた分散液の薄層を形成させて乾燥することを特徴とする、口腔内フィルム状製剤の製造方法。
1b 可食性高分子、又は可食性高分子と薬物を含有するフィルム
2a プローブ
2b 両面テープ
2c 試験片
2d コラーゲンフィルム
2e ゴム
2f 試験台
すなわち、0.2重量%のポリオキシエチレンモノラウリン酸エステルのクロロホルム溶液3mL中に、10mgの糖又は糖アルコール粒子を添加し、超音波により十分に分散させた。この分散液を、レーザー散乱式粒度分布測定装置(堀場製作所製、LA-950)における透過率が75%~85%を示すようにクロロホルムに添加し、湿式法により50容量%平均粒子径を測定した。
本発明に係る口腔内フィルム状製剤について、実施例1及び2の組成を、比較例1及び2の組成とともに表3に示す。
続いて、本発明の口腔内フィルム状製剤についての実施例3~10の組成を表4に示した。これらは実施例1及び2の口腔内フィルム状製剤と同様に、ゾルミトリプタンをエタノールに溶解し、次いで予め32μmの篩を篩過した糖又は糖アルコールの微粒子を加えて分散し、次いで、エタノール70.5重量部にHPCを加えて調製した溶液、及びポリエチレングリコールを加えて撹拌混合し、十分に脱泡後、これをポリエチレンテレフタレート製剥離フィルム上に延伸乾燥して、厚さ約100μmのフィルムを製造し、得られたフィルムを3cm2の長方形に裁断して調製した。
比較例3~13についての組成を表5に示した。
本発明に係る口腔内フィルム状製剤についての実施例11~20の組成を表6に示した。
本発明に係る口腔内フィルム状基剤についての実施例21~26の組成を表7に示した。
フィルム状製剤又は基剤を調製する際、ポリエチレンテレフタレート製剥離フィルムからの剥離性を評価し、次の評価基準に従ってスコア化した。
容易に剥離できる;4点
剥離できる;3点
剥離できるが、剥がしづらい;2点
剥離はできるが、フィルムが破損した;1点
全く剥離できない;0点
本試験は、「日本工業規格(JIS)L1096 一般織物試験法,8.19剛軟性, 8.19.1A法(45°カンチレバー法)」に準拠して行った。まず実施例及び比較例の各試料より、20mmx150mmの試験片を5枚採取し、一端が45°の斜面を有し、表面が滑らかな水平台の上に、試験片の短辺をスケールの基線に合わせて置く。次に、適当な方法により試験片を斜面の方向に緩やかに滑らせて、試験片の一端の中央点が斜面Aと接したときの他端の位置をスケールによって読む。剛軟度は試験片が移動した時の長さ(mm)で示され、5枚の試験片の表裏、前後をそれぞれ逆にして測定し、それぞれの平均値を算出して剛軟度として求めた。評価基準は、糖を添加しない場合のフィルム状製剤(比較例3)の剛軟度(約60mm)を基準として考え、次のように設定した。なお、調製した試料の物性上、剥離フィルムから剥離することができず、フィルム状製剤を得ることができなかったものについては、0点とした。
60±10mm以上20mm未満;4点
60±20mm以上30mm未満;3点
60±30mm以上40mm未満;2点
60±40mm以上;1点
本試験は、「日本工業規格(JIS)K7127 プラスチックフィルム及びシートの引張試験方法」に準拠して行った。各フィルム状製剤又は基剤を12mmx50mmに裁断して試験片とし、デシケーター中で十分に乾燥させた後、試験に供した。試験は、小型卓上引張試験機(島津製作所製、EZ TEST-100M)を用い、試験速度として毎分60mmを用いて行った。試験に供した試験片についてほとんど伸びが見られなかったため、測定により得られた引張降伏強さを引張強度として求めた。各試料について3回繰り返し測定し、その平均値を求めて引張強度とした。求めた引張強度は、次の評価基準に従ってスコア化した。なお、調製した試料の物性上、剥離フィルムから剥離することができず、フィルム状製剤を得ることができなかったものについては、0点とした。
引張強度=10N以上20N未満;4点
引張強度=5N以上10N未満;3点
引張強度=2N以上5N未満;2点
引張強度=2N未満;1点
本試験は、各フィルム状製剤又は基剤を直径12mmの円形に裁断して試験片とし、レオメーター(SUN SCIENTIFIC,CR-2000)を用いて行った。ここで、「タック」とは、軽い力で短時間に被着体に接触させた際に、被着体に粘着する力をいう。試験のようすを図2に示した。すなわち、直径12mmのプローブ2a上に両面テープ2bで前記試験片2cを貼付する。別途、試験台2fの上にはゴム2eを載せ、その上に水で浸したコラーゲンフィルム2dを設置する。試験片に200μLの精製水を添加し、試験片2cが貼付されたプローブ2aを下降させてコラーゲンフィルム2dに接触させ、次いで上昇させる。その際、プローブ2aがコラーゲンフィルム2dから離れる時に得られる初期タック後のタック持続時間を、記録紙よりノギスを用いて測定した。測定結果は、次の評価基準に従ってスコア化した。なお、調製した試料の物性上、剥離フィルムから剥離することができず、フィルム状製剤を得ることができなかったものについては、剥離フィルムごと裁断し、剥離フィルム側をプローブの両面テープに貼付し、同様に測定を行った。
タック持続時間測定値=2mm未満;4点
タック持続時間測定値=2mm以上3mm未満;3点
タック持続時間測定値=3mm以上4mm未満;2点
タック持続時間測定値=4mm以上;1点
1000mLのガラスシャーレにpH6.8のリン酸塩緩衝液900mLを入れ、この中にステンレス製篩(Φ4mm)を上下反転させて沈め、スターラーで撹拌(300rpm)する。この溶液の温度は、恒温水循環装置を用いて37±2℃で管理し、この中に試験片(3cm2)を沈め、同時に上から3cmx3cmのステンレス製金網(網目サイズ5mm)を重しとして載せた。試験片の崩壊のようすを目視にて観察し、試験片を沈めてから、試験片が完全に崩壊するまでの時間をストップウォッチで測定した。各試料について3回繰り返して測定し、その平均値を口腔内崩壊時間とした。この口腔内崩壊時間を次の評価基準に従ってスコア化した。なお、調製した試料の物性上、剥離フィルムから剥離することができず、フィルム状製剤を得ることができなかったものについては、0点とした。
口腔内崩壊時間=10秒未満;4点
口腔内崩壊時間=10秒以上15秒未満;3点
口腔内崩壊時間=15秒以上20秒未満;2点
口腔内崩壊時間=20秒以上;1点
各フィルム状製剤又は基剤を裁断して試験片とし、パネラーに、試験片を指で5秒間円を描くように触らせ、表面がネバネバするかどうかの違和感を次の評価基準に従って評価させた。なお、調製した試料の物性上、剥離フィルムから剥離することができず、フィルム状製剤を得ることができなかったものについては、0点とした。
ネバネバ感を感じない;4点
気にならない程度のネバネバ感である;3点
ネバネバ感に違和感を感じる;2点
かなりネバネバしており、指にフィルムが残る;1点
本発明の実施例21~23の口腔内フィルム状基剤について、添加したD-マンニトール微粒子A~Cのフィルム状基剤中における粒子径を、マイクロスコープ(キーエンス社製、VHX-600)を用いて測定した。粒子200個について測定した結果から、50容量%平均粒子径を求めた。
Claims (11)
- 水及び溶解パラメーターが9.7以上の有機溶媒に可溶性である可食性高分子の1種又は2種以上と、平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を含有する、口腔内フィルム状基剤。
- 糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子の平均粒子径が、0.1μm~30μmである、請求項1に記載の口腔内フィルム状基剤。
- 水及び溶解パラメーターが9.7以上の有機溶媒に可溶性である可食性高分子が、ポリビニルピロリドン及びヒドロキシプロピルセルロースよりなる群から選ばれる1種又は2種以上である、請求項1又は請求項2に記載の口腔内フィルム状基剤。
- ポリビニルピロリドンの重量平均分子量が、2,500~3,000,000である、請求項3に記載の口腔内フィルム状基剤。
- ヒドロキシプロピルセルロースの重量平均分子量が、10,000~1,200,000である、請求項3に記載の口腔内フィルム状基剤。
- ヒドロキシプロピルセルロースのヒドロキシプロポキシ基置換度が、50%~100%である、請求項3又は請求項5に記載の口腔内フィルム状基剤。
- 請求項1~請求項6のいずれか1項に記載した口腔内フィルム状基剤に、薬物を含有させてなる、口腔内フィルム状製剤。
- 溶解パラメーターが9.7以上の有機溶媒に、水及び該有機溶媒に可溶性である可食性高分子の1種又は2種以上、及び平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を溶解又は分散させ、得られた分散液の薄層を形成させて乾燥することを特徴とする、口腔内フィルム状基剤の製造方法。
- 溶解パラメーターが9.7以上の有機溶媒に、薬物、水及び該有機溶媒に可溶性である可食性高分子の1種又は2種以上、及び平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を溶解又は分散させ、得られた分散液の薄層を形成させて乾燥することを特徴とする、口腔内フィルム状製剤の製造方法。
- 溶解パラメーターが9.7以上の有機溶媒の一部に、水及び該有機溶媒に可溶性である可食性高分子の1種又は2種以上を溶解させ、該溶液を、平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を溶解パラメーターが9.7以上の有機溶媒の残部に分散させたものに加えて混合し、得られた分散液の薄層を形成させて乾燥することを特徴とする、口腔内フィルム状基剤の製造方法。
- 溶解パラメーターが9.7以上の有機溶媒の一部に、水及び該有機溶媒に可溶性である可食性高分子の1種又は2種以上を溶解させ、該溶液を、薬物と、平均粒子径が0.1μm~60μmである単糖~六糖の糖及びこれらの糖アルコールよりなる群から選ばれる1種又は2種以上の粒子を溶解パラメーターが9.7以上の有機溶媒の残部に溶解又は分散させたものに加えて混合し、得られた分散液の薄層を形成させて乾燥することを特徴とする、口腔内フィルム状製剤の製造方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200980155744.8A CN102300565B (zh) | 2009-01-29 | 2009-03-06 | 口腔内薄膜状基剂及制剂 |
ES09839222.8T ES2523969T3 (es) | 2009-01-29 | 2009-03-06 | Agente de base y formulación intraorales en forma de película |
EP09839222.8A EP2399574B1 (en) | 2009-01-29 | 2009-03-06 | Intraoral film-like base agent and formulation |
RU2011135837/15A RU2488385C2 (ru) | 2009-01-29 | 2009-03-06 | Пероральная основа в виде пленки |
JP2010548356A JP5674480B2 (ja) | 2009-01-29 | 2009-03-06 | 口腔内フィルム状基剤及び製剤 |
US13/146,829 US9289386B2 (en) | 2009-01-29 | 2009-03-06 | Oral film-form base and oral film-form preparation |
CA2750617A CA2750617C (en) | 2009-01-29 | 2009-03-06 | Oral film-form base and oral film-form preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2009/051511 WO2010086989A1 (ja) | 2009-01-29 | 2009-01-29 | 口腔内フィルム状基剤及び製剤 |
JPPCT/JP2009/051511 | 2009-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010087032A1 true WO2010087032A1 (ja) | 2010-08-05 |
Family
ID=42395259
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/051511 WO2010086989A1 (ja) | 2009-01-29 | 2009-01-29 | 口腔内フィルム状基剤及び製剤 |
PCT/JP2009/054335 WO2010087032A1 (ja) | 2009-01-29 | 2009-03-06 | 口腔内フィルム状基剤及び製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/051511 WO2010086989A1 (ja) | 2009-01-29 | 2009-01-29 | 口腔内フィルム状基剤及び製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9289386B2 (ja) |
EP (1) | EP2399574B1 (ja) |
KR (1) | KR101629992B1 (ja) |
CN (1) | CN102300565B (ja) |
CA (1) | CA2750617C (ja) |
ES (1) | ES2523969T3 (ja) |
RU (1) | RU2488385C2 (ja) |
WO (2) | WO2010086989A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2990030A1 (en) | 2014-08-27 | 2016-03-02 | Nitto Denko Corporation | Oral film-form base and preparation |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010086989A1 (ja) | 2009-01-29 | 2010-08-05 | 日東電工株式会社 | 口腔内フィルム状基剤及び製剤 |
JP5588688B2 (ja) * | 2010-01-28 | 2014-09-10 | 日東電工株式会社 | フィルム状製剤 |
JP5800527B2 (ja) * | 2010-03-30 | 2015-10-28 | 日東電工株式会社 | 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法 |
JP5751868B2 (ja) | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | フィルム状製剤及びその製造方法 |
JP5841433B2 (ja) * | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | 口腔内フィルム状基剤及び製剤 |
CN105682639B (zh) | 2013-07-31 | 2021-02-05 | 兰色制药医药工业股份有限公司 | 口腔可分散膜 |
CN105611918B (zh) * | 2014-06-24 | 2018-08-14 | 株式会社宇信乐宝贴剂 | 含有他达拉非的口腔崩解型膜制剂及其制备方法 |
KR102162330B1 (ko) * | 2018-12-27 | 2020-10-06 | 건양대학교산학협력단 | 천문동 추출물을 함유하는 구강붕해필름 조성물 및 그 제조 방법 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001504106A (ja) * | 1996-11-11 | 2001-03-27 | エルティエス ローマン テラピー―ズュステーメ アーゲー | 口部に適用される瞬時湿潤性の水溶性薄膜または水溶性層 |
JP2004043450A (ja) * | 2002-05-16 | 2004-02-12 | Kyukyu Yakuhin Kogyo Kk | 速溶性フィルム状製剤 |
JP2005342154A (ja) * | 2004-06-02 | 2005-12-15 | Kyukyu Yakuhin Kogyo Kk | 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤 |
JP2007509172A (ja) * | 2003-10-24 | 2007-04-12 | アドヒーシブズ・リサーチ・インコーポレイテッド | 医薬又は化粧用薬剤を送達するための迅速分解性フイルム |
JP2009051511A (ja) | 2007-08-23 | 2009-03-12 | Kobayashi Plastic Seisakusho:Kk | プルトップ缶 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN142428B (ja) | 1974-07-05 | 1977-07-09 | Schering Ag | |
JPS56802A (en) | 1979-06-15 | 1981-01-07 | Nippon Soda Co Ltd | Preparation of hydroxypropyl-cellulose |
GB8322007D0 (en) | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
US4639368A (en) | 1984-08-23 | 1987-01-27 | Farmacon Research Corporation | Chewing gum containing a medicament and taste maskers |
JPH05505680A (ja) | 1991-01-11 | 1993-08-19 | コーブ ラボラトリーズ インコーポレイテッド | 乾燥または凍結乾燥した細胞または細胞―様物質を使用する循環抗体の型を検定する方法 |
JP3496727B2 (ja) | 1993-12-27 | 2004-02-16 | 救急薬品工業株式会社 | 製剤用基剤 |
US6156343A (en) | 1994-12-27 | 2000-12-05 | Akzo Nobel N.V. | Controlled release preparation |
US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
US20010006677A1 (en) | 1996-10-29 | 2001-07-05 | Mcginity James W. | Effervescence polymeric film drug delivery system |
JPH10179045A (ja) | 1996-12-25 | 1998-07-07 | Osaka Kagaku Gokin Kk | シート状可食性成形物 |
FR2766708B1 (fr) * | 1997-07-30 | 2000-05-05 | Galenix Dev | Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention |
JP3460538B2 (ja) | 1997-10-08 | 2003-10-27 | 救急薬品工業株式会社 | 速溶性フィルム製剤 |
TW527195B (en) | 1997-10-09 | 2003-04-11 | Ssp Co Ltd | Fast-soluble solid pharmaceutical combinations |
JPH11116465A (ja) | 1997-10-09 | 1999-04-27 | Ss Pharmaceut Co Ltd | 迅速溶解性製剤およびその製造法 |
DE19837073A1 (de) | 1998-08-17 | 2000-03-23 | Lohmann Therapie Syst Lts | Folienförmige Wirkstoffträger |
JP3730081B2 (ja) | 2000-04-10 | 2005-12-21 | 大鵬薬品工業株式会社 | フィルム状トローチ |
JP2001318348A (ja) | 2000-05-11 | 2001-11-16 | Lion Corp | コンタクトレンズ装着液 |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
WO2003030883A1 (en) | 2001-10-12 | 2003-04-17 | Kosmos Pharma | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
WO2003030882A1 (en) | 2001-10-12 | 2003-04-17 | Kosmos Pharma | Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made thereform |
US20050008735A1 (en) * | 2002-02-11 | 2005-01-13 | Pearce Tony M. | Chocolate polymer snacks |
WO2006031209A1 (en) | 2003-05-28 | 2006-03-23 | Monosolrx Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
DE10207394B4 (de) | 2002-02-21 | 2007-03-29 | Lts Lohmann Therapie-Systeme Ag | Geschmacksmaskierte oblatenförmige Arzneizubereitung |
EP1504765B1 (en) | 2002-05-16 | 2015-07-22 | Kyukyu Pharmaceutical Co., Ltd. | Quickly soluble film preparations |
DE10224607B4 (de) | 2002-06-04 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Filmförmige, zerfallsfähige Zubereitungen zur Wirkstofffreisetzung und Verfahren zu deren Herstellung |
WO2004012707A1 (de) | 2002-07-24 | 2004-02-12 | Basf Aktiengesellschaft | Suspensionen von salzen der ascorbinsäure und ihre verwendung als antioxidantien |
WO2004047793A1 (en) | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Pharmaceutical allergen product |
US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
CN100356908C (zh) | 2003-01-30 | 2007-12-26 | 莫诺索尔克斯有限公司 | 具有非自聚集一致不均匀性的薄膜及由其制造的给药系统 |
WO2004080499A1 (en) | 2003-03-12 | 2004-09-23 | 3M Innovative Properties Company | Polymer compositions with bioactive silver, copper or zinc compounds, medical articles, and processes |
WO2004100993A1 (ja) | 2003-05-15 | 2004-11-25 | Menicon Co., Ltd. | 眼科用組成物 |
JP2005008568A (ja) | 2003-06-19 | 2005-01-13 | Menicon Co Ltd | 眼科用組成物 |
JP2005021124A (ja) | 2003-07-02 | 2005-01-27 | Kyukyu Yakuhin Kogyo Kk | 口腔用フィルム製剤 |
JP2005060244A (ja) | 2003-08-12 | 2005-03-10 | Chisso Corp | グルタチオン固定化磁性微粒子及びこれを用いたタンパク質の分離、精製方法 |
US20050079253A1 (en) | 2003-10-10 | 2005-04-14 | Hiroshi Nakamura | Bilayer edible sheet |
AU2005210637B2 (en) | 2004-01-30 | 2010-09-16 | A.V. Topchiev Institute Of Petrochemical Synthesis | Rapidly dissolving film for delivery of an active agent |
US20050186257A1 (en) | 2004-02-20 | 2005-08-25 | Todd Manegold | Dissolvable film and method of manufacture |
AU2005231416A1 (en) | 2004-04-01 | 2005-10-20 | Smithkline Beecham Corporation | Dissolvable tooth whitening strip |
AR051397A1 (es) | 2004-10-21 | 2007-01-10 | Novartis Ag | Composicion farmaceutica |
GB0508306D0 (en) * | 2005-04-25 | 2005-06-01 | Bioprogress Technology Ltd | Nicotine dosage forms |
DE102005033943A1 (de) | 2005-07-20 | 2007-02-22 | Hexal Ag | Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum |
CA2621263A1 (en) | 2005-09-09 | 2007-03-15 | Garry L. Myers | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
AU2006299310A1 (en) | 2005-10-04 | 2007-04-12 | Alk-Abello A/S | Solid vaccine formulation |
US20070098790A1 (en) | 2005-10-31 | 2007-05-03 | David Jiang | Nutritional supplement for the enhancement of the health of the liver |
DE602005011465D1 (de) | 2005-12-13 | 2009-01-15 | Nestec Sa | Selbstschäumende Küchenhilfsmittel und Verfahren |
WO2008002567A2 (en) * | 2006-06-27 | 2008-01-03 | Alza Corporation | Methods of treating conditions by sustained release administration of benzimidazole derivatives |
JP4916894B2 (ja) | 2007-01-11 | 2012-04-18 | 株式会社ツキオカ | フィルム状製剤及びフィルム状製剤の製造方法 |
AU2008206362A1 (en) | 2007-01-12 | 2008-07-24 | Monosol Rx Llc | High dose film compositions and methods of preparation |
WO2008149440A1 (ja) | 2007-06-07 | 2008-12-11 | Sato Pharmaceutical Co., Ltd. | 速溶性及び可撓性を有するフィルム製剤 |
WO2009099831A2 (en) | 2008-01-31 | 2009-08-13 | Mcneil-Ppc, Inc. | Edible film-strips with modified release active ingredients |
WO2009099830A2 (en) | 2008-01-31 | 2009-08-13 | Mcneil-Ppc, Inc. | Edible film-strips for immediate release of active ingredients |
CN102006863A (zh) | 2008-04-15 | 2011-04-06 | 盐野义制药株式会社 | 膜组合物 |
WO2010002418A2 (en) * | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
FR2933299B1 (fr) | 2008-07-04 | 2012-02-03 | Roquette Freres | Mannitol orodispersible |
TW201008569A (en) | 2008-08-08 | 2010-03-01 | Bayer Schering Pharma Ag | Progestin-containing drug delivery system |
JP2010158173A (ja) | 2009-01-06 | 2010-07-22 | Lintec Corp | 可食性フィルム、可食性フィルム用組成物及び可食性フィルム積層体の製造方法 |
JP5379499B2 (ja) | 2009-01-29 | 2013-12-25 | リンテック株式会社 | 嚥下物包装体および可食性フィルム接合体 |
WO2010086989A1 (ja) | 2009-01-29 | 2010-08-05 | 日東電工株式会社 | 口腔内フィルム状基剤及び製剤 |
PT2952191T (pt) | 2009-06-12 | 2018-11-30 | Sunovion Pharmaceuticals Inc | Apomorfina sublingual |
JP5588688B2 (ja) | 2010-01-28 | 2014-09-10 | 日東電工株式会社 | フィルム状製剤 |
-
2009
- 2009-01-29 WO PCT/JP2009/051511 patent/WO2010086989A1/ja active Application Filing
- 2009-03-06 KR KR1020117017814A patent/KR101629992B1/ko active IP Right Grant
- 2009-03-06 EP EP09839222.8A patent/EP2399574B1/en active Active
- 2009-03-06 US US13/146,829 patent/US9289386B2/en active Active
- 2009-03-06 CA CA2750617A patent/CA2750617C/en active Active
- 2009-03-06 RU RU2011135837/15A patent/RU2488385C2/ru active
- 2009-03-06 CN CN200980155744.8A patent/CN102300565B/zh active Active
- 2009-03-06 WO PCT/JP2009/054335 patent/WO2010087032A1/ja active Application Filing
- 2009-03-06 ES ES09839222.8T patent/ES2523969T3/es active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001504106A (ja) * | 1996-11-11 | 2001-03-27 | エルティエス ローマン テラピー―ズュステーメ アーゲー | 口部に適用される瞬時湿潤性の水溶性薄膜または水溶性層 |
JP2004043450A (ja) * | 2002-05-16 | 2004-02-12 | Kyukyu Yakuhin Kogyo Kk | 速溶性フィルム状製剤 |
JP2007509172A (ja) * | 2003-10-24 | 2007-04-12 | アドヒーシブズ・リサーチ・インコーポレイテッド | 医薬又は化粧用薬剤を送達するための迅速分解性フイルム |
JP2005342154A (ja) * | 2004-06-02 | 2005-12-15 | Kyukyu Yakuhin Kogyo Kk | 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤 |
JP2009051511A (ja) | 2007-08-23 | 2009-03-12 | Kobayashi Plastic Seisakusho:Kk | プルトップ缶 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2399574A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2990030A1 (en) | 2014-08-27 | 2016-03-02 | Nitto Denko Corporation | Oral film-form base and preparation |
KR20160025468A (ko) | 2014-08-27 | 2016-03-08 | 닛토덴코 가부시키가이샤 | 구강 내 필름형 기제 및 제제 |
US9439872B2 (en) | 2014-08-27 | 2016-09-13 | Nitto Denko Corporation | Oral film-form base and preparation |
Also Published As
Publication number | Publication date |
---|---|
CN102300565B (zh) | 2014-07-23 |
EP2399574A1 (en) | 2011-12-28 |
US9289386B2 (en) | 2016-03-22 |
WO2010086989A1 (ja) | 2010-08-05 |
KR20110117125A (ko) | 2011-10-26 |
CA2750617C (en) | 2016-05-10 |
EP2399574B1 (en) | 2014-11-12 |
CA2750617A1 (en) | 2010-08-05 |
KR101629992B1 (ko) | 2016-06-13 |
ES2523969T3 (es) | 2014-12-03 |
CN102300565A (zh) | 2011-12-28 |
RU2488385C2 (ru) | 2013-07-27 |
RU2011135837A (ru) | 2013-03-10 |
EP2399574A4 (en) | 2013-08-28 |
US20110293673A1 (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010087032A1 (ja) | 口腔内フィルム状基剤及び製剤 | |
JP3460538B2 (ja) | 速溶性フィルム製剤 | |
JP2011207847A (ja) | フィルム状製剤及びその製造方法 | |
JP5841433B2 (ja) | 口腔内フィルム状基剤及び製剤 | |
JP5588688B2 (ja) | フィルム状製剤 | |
JP5751868B2 (ja) | フィルム状製剤及びその製造方法 | |
JP5890110B2 (ja) | 可食性ゼリー状組成物、ゼリー状製剤及びゼリー状製剤の製造方法 | |
JP5674480B2 (ja) | 口腔内フィルム状基剤及び製剤 | |
JP6574556B2 (ja) | 口腔内フィルム状基剤及び製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980155744.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09839222 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2010548356 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2750617 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13146829 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20117017814 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009839222 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6472/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011135837 Country of ref document: RU |